In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

U3 Pharma AG

http://u3pharma.com/

Latest From U3 Pharma AG

New Daiichi Structure Strengthens Oncology Focus

Japanese firm creates new US-based global organization that reaffirms strategic focus on oncology as main pillar of mid-term growth.

Business Strategies Cancer

Oncology Deal-Making The Daiichi Way

Daiichi Sankyo’s relatively young strategic pivot into oncology is paying major dividends, with two huge global deals with AstraZeneca now in the bag within 18 months. Scrip takes a closer look with the help of insights from the Japanese firm’s global oncology R&D head.

Commercial Deals

Daiichi Denies OTC Business Sale But Would It Make Sense?

Daiichi Sankyo denies report it is in negotiations to sell its OTC business, but might such a move actually align well with mid-term strategy?

Japan OTC Drugs

Daiichi Sankyo Realigns Japan R&D As Oncology Comes To Fore

Daiichi Sankyo unveils further restructuring moves, this time mainly in its R&D functions in Japan, as part of an ongoing strategic pivot towards oncology.

Japan Cancer
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Other Names / Subsidiaries
    • Daiichi Sankyo Co., Ltd
UsernamePublicRestriction

Register